24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Guillain-Barré syndrome.

      1 , 2 , 3
      Lancet (London, England)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100,000 people developing the disorder every year worldwide. Under the umbrella term of Guillain-Barré syndrome are several recognisable variants with distinct clinical and pathological features. The severe, generalised manifestation of Guillain-Barré syndrome with respiratory failure affects 20-30% of cases. Treatment with intravenous immunoglobulin or plasma exchange is the optimal management approach, alongside supportive care. Understanding of the infectious triggers and immunological and pathological mechanisms has advanced substantially in the past 10 years, and is guiding clinical trials investigating new treatments. Investigators of large, worldwide, collaborative studies of the spectrum of Guillain-Barré syndrome are accruing data for clinical and biological databases to inform the development of outcome predictors and disease biomarkers. Such studies are transforming the clinical and scientific landscape of acute autoimmune neuropathies.

          Related collections

          Author and article information

          Journal
          Lancet
          Lancet (London, England)
          1474-547X
          0140-6736
          Aug 13 2016
          : 388
          : 10045
          Affiliations
          [1 ] Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Electronic address: Hugh.Willison@glasgow.ac.uk.
          [2 ] Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
          [3 ] Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
          Article
          S0140-6736(16)00339-1
          10.1016/S0140-6736(16)00339-1
          26948435
          2b3ae9dc-eee0-4a0e-879c-79aaf4102689
          Copyright © 2016 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article